We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 16.60 | 1.72% | 981.00 | 982.80 | 983.20 | 986.20 | 965.00 | 965.00 | 4,932,607 | 16:35:03 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Ortho,prosth,surg Appl,suply | 5.55B | 263M | 0.3011 | 32.65 | 8.59B |
From Apr 2022 to Apr 2024
TIDMSN.
RNS Number : 8443X
Smith & Nephew Plc
01 September 2022
1 September 2022
Board Committee Membership
Smith & Nephew plc (LSE:SN, NYSE:SNN) announces that the Board has resolved to appoint Jo Hallas, Independent Non-Executive Director, as a member of the Audit Committee and Angie Risley, Independent Non-Executive Director, as a member of the Nomination & Governance Committee. Both appointments are effective 1 September 2022.
This announcement has been made in accordance with the requirements of 9.6.11(3) of the Listing Rules.
Enquiries
Investors Andrew Swift +44 (0) 1923 477433 Smith+Nephew Media Charles Reynolds +44 (0) 1923 477314 Smith+Nephew Susan Gilchrist / Ayesha Bharmal +44 (0) 20 7404 5959 Brunswick
About Smith+Nephew
Smith+Nephew is a portfolio medical technology company that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter ,
LinkedIn , Instagram or Facebook .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCFLFITTTILVIF
(END) Dow Jones Newswires
September 01, 2022 02:02 ET (06:02 GMT)
1 Year Smith & Nephew Chart |
1 Month Smith & Nephew Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
